<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01766440</url>
  </required_header>
  <id_info>
    <org_study_id>RD.06. SPR.18104</org_study_id>
    <nct_id>NCT01766440</nct_id>
  </id_info>
  <brief_title>PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis</brief_title>
  <official_title>Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the calcitriol absorption in pediatric subjects
      is comparable to that in adults and adolescents, with no significant impact on
      calcium/phosphorus metabolism.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of Calcitriol Plasma Level</measure>
    <time_frame>Day 14</time_frame>
    <description>Cmax of calcitriol plasma level at Day 14 (Peak plasma concentration of calcitriol from Day 1 to Day 14)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin of Calcitriol Plasma Level</measure>
    <time_frame>Day 14</time_frame>
    <description>Cmin of calcitriol plasma level at Day 14</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Calcitriol Plasma Level</measure>
    <time_frame>Day 14</time_frame>
    <description>Tmax of calcitriol plasma level at Day 14</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-6h) of Calcitriol Plasma Level</measure>
    <time_frame>Day 14</time_frame>
    <description>AUC (0-6h) of calcitriol plasma level at Day 14 (Pre-dose to 6 hours post-dose)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-9h) of Calcitriol Plasma Level</measure>
    <time_frame>Day 14</time_frame>
    <description>AUC (0-9h) of calcitriol plasma level at Day 14 (Pre-dose to 9 hours post-dose. For subjects with a body weight of &lt;15 kg, AUC (0-9h) was extrapolated based on the pre-dose to 6 hours post-dose PK samples.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-12h) of Calcitriol Plasma Level</measure>
    <time_frame>Day 14</time_frame>
    <description>AUC (0-12h) of calcitriol plasma level at Day 14 (For subjects with a body weight of &lt; 15 kg, AUC (0-9h) was extrapolated based on the pre-dose to 6 hours post dose PK samples. For subjects with a body weight of â‰¥ 15 kg, AUC (0-12h) was extrapolated based on the pre-dose to 9 hours post-dose PK samples.)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Calcitriol 3 mcg/g ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical application every 12 hours for 14 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitriol 3 mcg/g ointment</intervention_name>
    <description>Topical ointment; twice daily application</description>
    <arm_group_label>Calcitriol 3 mcg/g ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female pediatric subjects, 2 to 12 years of age inclusive at screening

          -  Clinical diagnosis of plaque type psoriasis involving 3% through 35% body surface area
             at screening and baseline (excluding face and scalp)

        Exclusion Criteria:

          -  Subjects with guttate or pustular psoriasis, erythrodermic psoriasis or active
             infection

          -  Vitamin D deficiency at screening

          -  Subjects with hypercalcemia and out of range urinary calcium/creatinine ratio at
             screening

          -  Subjects with secondary hyperparathyroidism at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Graeber, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Galderma R&amp;D, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rady Children's Hospital - Pediatric and Adolescent Dermatology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Dermatology and Skin Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Menter Dermatology Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2013</study_first_submitted>
  <study_first_submitted_qc>January 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2013</study_first_posted>
  <results_first_submitted>February 15, 2017</results_first_submitted>
  <results_first_submitted_qc>February 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 31, 2017</results_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Calcitriol 3 mcg/g Ointment</title>
          <description>Topical application every 12 hours for 14 consecutive days
Calcitriol 3 mcg/g ointment: Topical ointment; twice daily application</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Calcitriol 3 mcg/g Ointment</title>
          <description>Topical application every 12 hours for 14 consecutive days
Calcitriol 3 mcg/g ointment: Topical ointment; twice daily application</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.4" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Calcitriol Plasma Level</title>
        <description>Cmax of calcitriol plasma level at Day 14 (Peak plasma concentration of calcitriol from Day 1 to Day 14)</description>
        <time_frame>Day 14</time_frame>
        <population>Safety population: All enrolled subjects having received the treatment at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>Calcitriol 3 mcg/g Ointment</title>
            <description>Topical application every 12 hours for 14 consecutive days
Calcitriol 3 mcg/g ointment: Topical ointment; twice daily application</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Calcitriol Plasma Level</title>
          <description>Cmax of calcitriol plasma level at Day 14 (Peak plasma concentration of calcitriol from Day 1 to Day 14)</description>
          <population>Safety population: All enrolled subjects having received the treatment at least once.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.7" spread="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmin of Calcitriol Plasma Level</title>
        <description>Cmin of calcitriol plasma level at Day 14</description>
        <time_frame>Day 14</time_frame>
        <population>Safety population: All enrolled subjects having received the treatment at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>Calcitriol 3 mcg/g Ointment</title>
            <description>Topical application every 12 hours for 14 consecutive days
Calcitriol 3 mcg/g ointment: Topical ointment; twice daily application</description>
          </group>
        </group_list>
        <measure>
          <title>Cmin of Calcitriol Plasma Level</title>
          <description>Cmin of calcitriol plasma level at Day 14</description>
          <population>Safety population: All enrolled subjects having received the treatment at least once.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.6" spread="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Calcitriol Plasma Level</title>
        <description>Tmax of calcitriol plasma level at Day 14</description>
        <time_frame>Day 14</time_frame>
        <population>Safety population: All enrolled subjects having received the treatment at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>Calcitriol 3 mcg/g Ointment</title>
            <description>Topical application every 12 hours for 14 consecutive days
Calcitriol 3 mcg/g ointment: Topical ointment; twice daily application</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Calcitriol Plasma Level</title>
          <description>Tmax of calcitriol plasma level at Day 14</description>
          <population>Safety population: All enrolled subjects having received the treatment at least once.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-6h) of Calcitriol Plasma Level</title>
        <description>AUC (0-6h) of calcitriol plasma level at Day 14 (Pre-dose to 6 hours post-dose)</description>
        <time_frame>Day 14</time_frame>
        <population>Safety population: All enrolled subjects having received the treatment at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>Calcitriol 3 mcg/g Ointment</title>
            <description>Topical application every 12 hours for 14 consecutive days
Calcitriol 3 mcg/g ointment: Topical ointment; twice daily application</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-6h) of Calcitriol Plasma Level</title>
          <description>AUC (0-6h) of calcitriol plasma level at Day 14 (Pre-dose to 6 hours post-dose)</description>
          <population>Safety population: All enrolled subjects having received the treatment at least once.</population>
          <units>pg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="650.3" spread="166.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-9h) of Calcitriol Plasma Level</title>
        <description>AUC (0-9h) of calcitriol plasma level at Day 14 (Pre-dose to 9 hours post-dose. For subjects with a body weight of &lt;15 kg, AUC (0-9h) was extrapolated based on the pre-dose to 6 hours post-dose PK samples.)</description>
        <time_frame>Day 14</time_frame>
        <population>Safety population: All enrolled subjects having received the treatment at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>Calcitriol 3 mcg/g Ointment</title>
            <description>Topical application every 12 hours for 14 consecutive days
Calcitriol 3 mcg/g ointment: Topical ointment; twice daily application</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-9h) of Calcitriol Plasma Level</title>
          <description>AUC (0-9h) of calcitriol plasma level at Day 14 (Pre-dose to 9 hours post-dose. For subjects with a body weight of &lt;15 kg, AUC (0-9h) was extrapolated based on the pre-dose to 6 hours post-dose PK samples.)</description>
          <population>Safety population: All enrolled subjects having received the treatment at least once.</population>
          <units>pg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="952.6" spread="235.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-12h) of Calcitriol Plasma Level</title>
        <description>AUC (0-12h) of calcitriol plasma level at Day 14 (For subjects with a body weight of &lt; 15 kg, AUC (0-9h) was extrapolated based on the pre-dose to 6 hours post dose PK samples. For subjects with a body weight of â‰¥ 15 kg, AUC (0-12h) was extrapolated based on the pre-dose to 9 hours post-dose PK samples.)</description>
        <time_frame>Day 14</time_frame>
        <population>Safety population: All enrolled subjects having received the treatment at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>Calcitriol 3 mcg/g Ointment</title>
            <description>Topical application every 12 hours for 14 consecutive days
Calcitriol 3 mcg/g ointment: Topical ointment; twice daily application</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-12h) of Calcitriol Plasma Level</title>
          <description>AUC (0-12h) of calcitriol plasma level at Day 14 (For subjects with a body weight of &lt; 15 kg, AUC (0-9h) was extrapolated based on the pre-dose to 6 hours post dose PK samples. For subjects with a body weight of â‰¥ 15 kg, AUC (0-12h) was extrapolated based on the pre-dose to 9 hours post-dose PK samples.)</description>
          <population>Safety population: All enrolled subjects having received the treatment at least once.</population>
          <units>pg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1268.9" spread="307.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Calcitriol 3 mcg/g Ointment</title>
          <description>Topical application every 12 hours for 14 consecutive days
Calcitriol 3 mcg/g ointment: Topical ointment; twice daily application</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated early due to slow enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michael Graeber</name_or_title>
      <organization>Galderma</organization>
      <phone>(817)961-5000</phone>
      <email>michael.graeber@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

